



ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, N.J. 08933-7002

Please respond to: Centocor, Inc. 145 King of Prussia Road Radnor, PA 19087

> Phone: 610-651-7577 Facsimile: 610-651-6940

> > January 22, 2004

Sent via express mail EU 735850466US Mail Stop: IDS Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Re:

IDS for CEN 5015 USNP

Title: Epitope-Tagged Recombinant Growth Arrest Specific

Gene 6 Protein

Inventors: Jing Yang et al Company: CENTOCOR, INC.

**CORRECTED SERIAL NUMBER –** 

**SHOULD READ 10/671,054 - MAILED JANUARY 16, 2004** 

Per my telephone conversation this date with the USPTO office, I am attaching copy of original cover letter and forms for your easy reference. These papers were mailed January 16, 2004. Please note correction of serial number.

Thank you for your attention to this matter.

Sincerely, Marie C. Lucas

Marie C. Lucas Assistant to

Kenneth J. Dow

Assistant Patent Counsel

32,890

Attachment

/	OIPE
	JAN 2 2 2004
	TRADEMARKO

10/671,054	,
Serial No. 60/4/3,157	Docket No. CENSOLS USNP By: KD
Application of : Jing young et al	Mailed: January 167-2004 ecombing nt Growth Arrest
Entitled: Epitope-Tagged R	ecombinant Growth Arrest
specific Gene 6 Proti	ein
THE FOLLOWING HAS BEEN RECEIVED IN THE	U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:
☐ Oath or Declaration	☐ MPEP 609/
☐ Assignment	☐ Notice of Appeal
☐ Charge to Deposit Account 10-0750	☐ Brief
☐ Amendment	☐ Priority Document
☐ Extension of Time	☐ Status Inquiry
☐ Issue Fee Transmittal	☐ Sequence Listings/Diskette
□ PCT Filing	☐ Biological Deposit Declaration
<b>図</b> IDS-Form 1449	10 Other Postcard
,1	a Cover Sheet
	a Publications



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : JING YANG ET AL

Serial No.: 60/413,157 10/671,054 Art Unit:

Filed

SEPTEMBER 24, 2003

Examiner:

For

: EPITOPE-TAGGED RECOMBINANT GROWTH ARREST SPECIFIC

GENE 6 PROTEIN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

JANUARY 14, 2004
(Date of Deposit)

KENNETH J. DOW (Name of applicant, assignee, or Registered Representative)

JANUARY 14, 2004

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In a	ccordance with §1.129(a), this Information
Disclosure Stat	tement is being filed in connection with $\square$ the
first or 🗌 seco	ond After Final Submission, therefore:
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-0750/CEN
	5015 USNP/KD the fee of $$180.00$ as set forth in
	§1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

·	Statement in Accordance with §1.97(e)  (attached); or  Please charge Deposit Account No. 10-0750/CEN  5015 USNP/KD the fee of \$180.00 as set forth in  §1.17(p).	
	In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).	
	Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.	
	Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:	
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.	
1	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	·
	Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not	·
,	- 3 -	

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

∑ The	ere are no	listed	references	which	are not	in the
English langu	ıage.					
-						
The	e relevance	of the	se listed	referen	ces whi	ch are
not in the Er	nglish lang	uage is	as follows	s:		
☐ At	tached are	copies	of search	report (	(s) from	
corresponding	g patent ap	plicati	on(s), which	ch are	listed	on the
attached Subr	mission Und	ler MPEP	609 D.			
☐ At	tached are	the fol	llowing non	-publis	shed pen	ding
patent applic	cations whi	.ch may	be deemed	relevar	nt, which	h are
listed on the	e attached	Submiss	sion Under	MPEP 60	)9 D.	

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN 5015 USNP/KD. This form is submitted in triplicate.

Respectfully submitted,

KENNETH J. DOW Reg. No. 32,890

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 651-7422

DATED: JANUARY 16, 2004

ork Reduction Act of 1995, no persons are required to resp

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

and to a confection of insormation chicas it disp	sidyo a raila omo contro
Application Number	60/413,157/0/671054
Filing Date	SEPTEMBER 24, 2003
First Named Inventor	JING YANG
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5015 USNP

		U.S. Patent Document		Control of Applicant	Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	
	<u> </u>	US 5,538,861		Schneider et al	07-23-1996		
	<del>                                     </del>	US 5,585,269		Earp, III et al	12-17-1996		
		US 5,888,722		Costa De Beauregard et al	03-30-1999		
		US 5,955,420		Chen et al	09-21-1999		
	<b></b>	US 6,033,660		Mather et al	03-07-2000		
	1	US 6,169,070	B1	Chen et al	01-02-2001		
		US 6,211,142	B1	Hammonds et al	04-03-2001		
	<b>†</b>	US 6,255,068	B1	Godowski et al	07-03-2001		
	1						
	1						
		<b>†</b>					
	-						

		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number⁴	KindCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	. T⁵
		wo	99/49894	A1		10-07-1999		
	<u> </u>	wo	00/53754	A1		09-14-2000		<u> </u>
		wo	00/76309	АЗ		12-21-2000		
		wo	01/78778	A1		10-25-2001		
								<u> </u>
	<del>                                     </del>							
<b></b>	<del> </del>	<u></u>						

	 		_
Cyaminas	Date		1
Examiner	Considered	<u> </u>	
Signature	Condidated		_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P. O. Box 1450. Alexandria. VA 22313-1450.

1450, Alexandria, VA 22313-1450.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



PTO/S8/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

ond to a concetion of internacion and account						
Application Number	60/413,157 10/67/054					
Filing Date	SEPTEMBER 24, 2003					
First Named Inventor	JING YANG					
Group Art Unit						
Examiner Name						
Attorney Docket Number	CEN 5015 USNP					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item				
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>			
Initials*	No.1	publisher city and/or country where published	L			
(1.1104.0	1,151	AAANEIOLETTE ET AL. "The Protein Encoded by a Growth Arrest-Specific Gene (gas6) is a New Member of the Vitamon K-				
		Dependent Proteins Related to Protein S, A Negative Coregulator in the Blood Coagulation Cascade," Molecular and	İ			
		1 Callular Biology 1992, pages 4976-4985, Vol. 13				
		NAKANO ET AL, "Requirement of y-carbonxyglutamic acid residues for the biological activity of Gas6: contribution of				
		endogeneous Gas6 to the proliferation of vascular smooth muscle cells," J. Biochem, 1997, pages 387-392, Vol. 323, Great	1			
		Britain.				
		NAGATA ET AL, "Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Ax1, Sky, and Mer				
		Receptor Tyrosine Kinases," Journal of Biological Chemistry, 1996, pages 30022-30027, Vol. 271, No. 47, U.S.A.				
		MARK ET AL, "Characterization of Gas6, a Member of the Superfamily of G Domain-containing Proteins, as a Ligand for				
		Rse and Ax1," Journal of Biological Chemistry, 1996, pages 9785-9789, Vol. 271, No. 16, USA.  KNAPPIK ET AL, "An Improved Affinity Tag Based on the FLAG® Peptide for the Detection and Purification of Recombinant				
		Antibody Fragments," BioTechniques, 1994, pages 754-761, Vol. 17, No. 4, Switzerland.	1			
		BRIZZARD ET AL, "Epitope Tagging of Recombinant Proteins," Current Protocols in Neuroscience, Molecular Neuroscience,				
		1 1007 Pages 5.9.1 - 5.9.10, John Wiley & Sons Inc. United Kinddom				
		CHUBET et al, "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells,"				
		BioTechniques, 1996, pages 136-141, Vol. 20.				
			<u> </u>			
			<u> </u>			
			<b>└</b>			
	•		-			
			<b>├</b> ──			
		·	-			
			╂			
			<del> </del>			
	ļ		<del> </del>			
			<del> </del>			
			$\vdash$			
	1		+			
	<u> </u>		-			
	<b> </b>		<del> </del>			
	1		ــــــــــــــــــــــــــــــــــــــ			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.